Oncotarget.net features press releases on the latest oncology research, as well as interviews from the distinguished network of authors who continue to publish their research with Oncotarget.

Tag: head and neck squamous cell carcinoma

Figure 4: Everolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts.

Oncotarget

Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway

February 9, 2023

“[...] we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” Listen to an audio version of this press release BUFFALO, NY- February 9, 2023 – A new… read more

Oncotarget

Oncotarget | Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma

November 3, 2022

“In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.” Listen to an audio… read more

Figure 1: Development of an NF-κB activity related RNA expression classifier.

Oncotarget

Oncotarget | NF-κB Over-Activation Portends Improved Outcomes in HPV+ HNSCC

May 25, 2022

“Since clinicians are exploring therapeutic deintensification for HPV+ HNSCC, identifying patients with good or poor prognosis using the NF-κB Activity Classifier may be useful to guide therapeutic decisions.” Listen to… read more

Dr. Brian Van Tine and Dr. Charles Schutt from Washington University in St. Louis

Oncotarget

Behind the Study: Genomic, Neoantigen Evolution in Head, Neck Cancer

January 10, 2022

Dr. Brian Van Tine and Dr. Charles Schutt from Washington University in St. Louis discuss their 2021 research published by Oncotarget, entitled, “Genomic and neoantigen evolution from primary tumor to first metastases in… read more